You are here: Industry Insights > Opdivo

News List

Bristol-Myers' Opdivo fails brain tumor test again, this time in new patients fiercepharma
May 12, 2019
Cancer immunotherapies can effectively tackle many tumor types. But for notoriously hard-to-treat brain cancer—and after a couple of failed trials—hope seems less realistic, at least for Bristol-Myers Squibb’s Opdivo.
Bristol-Myers Squibb's Opdivo fails to hit survival goal in study of patients with newly diagnosed MGMT-unmethylated glioblastoma multiforme firstwordpharma
May 10, 2019
Bristol-Myers Squibb said Thursday that a Phase III study evaluating Opdivo (nivolumab) plus radiation versus temozolomide plus radiation in patients with newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM) failed to ...
Bristol-Myers Squibb and Infinity to collaborate on Opdivo (nivolumab) plus IPI-549 solid tumours study europeanpharmaceuticalreview
May 08, 2019
Bristol-Myers Squibb and Infinity will collaborate on a solid tumours trial to evaluate Bristol-Myers Squibb’s Opdivo in combination with Infinity’s…
NICE asks BMS for more data before approving cancer drug europeanpharmaceuticalreview
May 08, 2019
NICE has asked Bristol Myers Squibb, who manufacture nivolumab (Opdivo), to provide more information on its effectiveness for treating Hodgkin lymphoma…
How are the First Lung Cancer Patients Treated with Opdivo 4.5 Years Later? PharmaSources/Yefenghong
April 29, 2019
Since Opdivo was approved, it has started its unbelievable road, and has so far been approved 17 indications by the FDA.
Merck heaps early pressure on Bristol-Myers' Opdivo with Keytruda's kidney cancer debut fiercepharma
April 23, 2019
Bristol-Myers Squibb investors knew trouble would come for Opdivo when Merck’s Keytruda entered the kidney cancer arena, but that trouble just arrived two months early.
Nobel laureate behind Bristol-Myers' I-O superstar Opdivo demands a bigger cut fiercepharma
April 12, 2019
Opdivo, the blockbuster cancer drug Bristol-Myers Squibb co-developed with Japan’s Ono Pharmaceutical, is a cash cow in the global market. But a Nobel laureate who helped create the drug isn’t happy with his cut.
BMS, clinging to Opdivo's lung cancer share, highlights long-term data fiercepharma
April 04, 2019
After a hard blow to its hopes in previously untreated lung cancer, Bristol-Myers Squibb is clinging to its share of the second-line market.
Keytruda could get patient-friendly 6 week dosing schedule in EU pharmaphorum
March 07, 2019
US-based Merck & Co is putting further pressure on its arch-rival Bristol-Myers Squibb with a potential new six-week dosing schedule for some European patients taking its Keytruda (pembrolizumab) cancer immunotherapy.
Opdivo Plus Yervoy Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer americanpharmaceuticalreview
February 18, 2019
Bristol-Myers Squibb Company announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer (mCRPC)....

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page